Document is current
Any future updates will be listed below
-
Authors
Dietlein, Felix https://orcid.org/0000-0002-6651-7155
Weghorn, Donate https://orcid.org/0000-0001-7722-8618
Taylor-Weiner, Amaro
Richters, André
Reardon, Brendan
Liu, David
Lander, Eric S. https://orcid.org/0000-0003-2662-4631
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
Sunyaev, Shamil R. https://orcid.org/0000-0001-5715-5677
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 MH101244, R35 GM127131, U01 HG009088, K08 CA188615, R01 CA227388, R21 CA242861)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
European Molecular Biology Organization (ALTF 502-2016)
Amazon Web Services
Claudia Adams Barr Program for Innovative Cancer Research ASPIRE Award of The Mark Foundation for Cancer Research
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Phillip A. Sharp Innovation in Collaboration Award ASPIRE Award of The Mark Foundation for Cancer Research
- License Information
-
More Information
Article History
Received: 17 May 2019
Accepted: 16 December 2019
First Online: 3 February 2020
Competing interests
: E.M.V.A. is a consultant for Tango Therapeutics, Genome Medical, Invitae, Foresite Capital, Dynamo and Illumina. E.M.V.A. received research support from Novartis and BMS as well as travel support from Roche and Genentech. E.M.V.A. is an equity holder of Syapse, Tango Therapeutics and Genome Medical.
